Gene Expression Signature of Normal Cell-of-Origin Predicts Ovarian Tumor Outcomes

• Melissa A. Merritt,

  Affiliations Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Brigham and Women’s Hospital, Boston, Massachusetts, United States of America, Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts, United States of America

  ⨯
• Stefan Bentink,

  Affiliation Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America

  ⨯
• Matthew Schwede,

  Affiliation Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America

  ⨯
• Marcin P. Iwanicki,

  Affiliation Department of Cell Biology, Harvard Medical School, Boston, Massachusetts, United States of America

  ⨯
• John Quackenbush,

  Affiliation Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America

  ⨯
• Terri Woo,

  Affiliation Division of Women's and Perinatal Pathology, Department of Pathology, Brigham and Women’s Hospital, Boston, Massachusetts, United States of America

  ⨯
• Elin S. Agoston,

  Affiliation Division of Women's and Perinatal Pathology, Department of Pathology, Brigham and Women’s Hospital, Boston, Massachusetts, United States of America

  ⨯
• Ferenc Reinhardt,

  Affiliation Division of Women's and Perinatal Pathology, Department of Pathology, Brigham and Women’s Hospital, Boston, Massachusetts, United States of America

  ⨯
• Christopher P. Crum,

  Affiliation Division of Women's and Perinatal Pathology, Department of Pathology, Brigham and Women’s Hospital, Boston, Massachusetts, United States of America

  ⨯
• Ross S. Berkowitz,

  Affiliation Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Brigham and Women’s Hospital, Boston, Massachusetts, United States of America

  ⨯
• Samuel C. Mok,

  Affiliations Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Brigham and Women’s Hospital, Boston, Massachusetts, United States of America, Department of Gynecologic Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America

  ⨯
• Abigail E. Witt,

  Affiliation Department of Pathology, Interdisciplinary Stem Cell Institute and Braman Family Breast Cancer Institute, Miller School of Medicine, University of Miami, Miami, Florida, United States of America

  ⨯
• Michelle A. Jones,

  Affiliation Department of Pathology, Interdisciplinary Stem Cell Institute and Braman Family Breast Cancer Institute, Miller School of Medicine, University of Miami, Miami, Florida, United States of America

  ⨯
• Bin Wang,

  Affiliation Department of Pathology, Interdisciplinary Stem Cell Institute and Braman Family Breast Cancer Institute, Miller School of Medicine, University of Miami, Miami, Florida, United States of America

  ⨯
• Tan A. Ince

  * E-mail: TInce@med.miami.edu

  Affiliations Division of Women's and Perinatal Pathology, Department of Pathology, Brigham and Women’s Hospital, Boston, Massachusetts, United States of America, Department of Pathology, Interdisciplinary Stem Cell Institute and Braman Family Breast Cancer Institute, Miller School of Medicine, University of Miami, Miami, Florida, United States of America

  ⨯